Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer

Anticancer Res. 2018 Aug;38(8):4827-4831. doi: 10.21873/anticanres.12793.

Abstract

Background/aim: Secure dose escalation is required to compensate avoidance of concurrent chemotherapy in radiotherapy for increasing elderly bladder cancer. We aimed to evaluate the efficacy of lipiodol submucosally injected as a fiducial marker during image-guided radiotherapy (Lip-IGRT) for muscle invasive bladder cancer (BC).

Patients and methods: Twenty-three patients with T2a-4aN0-1M0 BC underwent whole-bladder irradiation of 46 Gy and Lip-IGRT of 20 Gy, conventionally. The bladder volume exposed to 19 Gy (bV19:%) on Lip-IGRT was referred as an index predicting cystitis.

Results: Lipiodol consistently highlighted the boundaries of 20 tumors (88%) on planning and portal verification images. Three of 4 patients under oral anticoagulant agents usage were complicated with grade ≥2 hematuria for 3 days (a patient with a bV19 of >50%) or more than a year (2 patients with bV19 of <50%) after the injection. The 3-year overall survival and disease-free survival rates were 70.4% and 71.1%, respectively.

Conclusion: Lipiodol marking is an effective way of demarcating BC. However, it is necessary to address the comorbidities of elderly patients.

Keywords: Radiotherapy; lipiodol marking; urinary bladder.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aging
  • Comorbidity
  • Disease-Free Survival
  • Ethiodized Oil / administration & dosage*
  • Female
  • Fiducial Markers*
  • Humans
  • Male
  • Middle Aged
  • Muscle Neoplasms / secondary
  • Prospective Studies
  • Radiotherapy, Image-Guided / methods*
  • Urinary Bladder / pathology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / radiotherapy*

Substances

  • Ethiodized Oil